NCT00783107CompletedPhase 1
Clinical Investigation of Aerosol Immunotherapy in COPD: A Phase I Placebo-Controlled Dose Escalation/Deescalation Trial of Aerosol Cyclosporine (CyIS) in Patients With Gold Stage III Chronic Obstructive Pulmonary Disease
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- University of Pittsburgh
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- To evaluate the safety and effectiveness of aerosol cyclosporine (CyIS) an immunomodulating therapeutic in treating COPD
Study Overview
Brief Summary
This is a randomized, double-blinded, Phase I dose escalation-deescalation protocol (DEP) of cyclosporine inhalation solution in patients with Gold Stage III chronic obstructive pulmonary disease.
The purpose of the study is to evaluate the safety and effectiveness of aerosolized Cyclosporine in treating COPD.
The specific aims of the study are:
- To identify the short term (28 day) safety profile of CyIS immunotherapy in severe COPD (GOLD III) patients with particular attention to airway reactivity and infection risk.
- To identify the pharmacokinetic-pharmacodynamic relationship of CyIS using peripheral blood markers of an adaptive immune response as endpoints in subjects with severe COPD (GOLD III) treated short-term.
Subjects between 45 and 70 years of age with a confirmed diagnosis of COPD, Gold Stage III, and meet all the study requirements, will be enrolled in this study. A total of 24 subjects of either sex will be enrolled in this study. A total of 4 subject cohorts (n=6) will participate in the protocol.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 45 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age between 45 and 70 years.
- •A confirmed diagnosis of COPD, Gold Stage III, using current accepted diagnostic criteria, including clinical/laboratory findings, pulmonary function tests, and appropriate history to exclude other disorders that could explain their lung disease.
- •Subjects agree to maintain a stable medication regimen in the absence of a disease flare
- •ECOG performance status of 0, 1, or
- •pCO2 < 45 mm Hg, room air oxyhemoglobin saturation > 85%
- •A willingness to participate in all portions of the protocol, including serial bronchoscopy, requisite surveillances, and ancillary immunologic studies in follow-up visits at this institution.
- •For woman of childbearing age, a negative pregnancy test, and a willingness to use two methods of contraception, or abstinence, and undergo monthly pregnancy testing.
- •Elevated T-cell cytokine gene expression, defined as baseline values > the mean of the pilot Gold 0-1 study population for one variable (CD4+IL-2 >23%, CD8+IFN-g >17%, CD8+MHC > 6%, or CD8 TGF-b).
- •An ability and willingness to provide written informed consent.
Exclusion Criteria
- •Three, or more exacerbations of lower respiratory disease in the past year requiring systemic corticosteroids, or one exacerbation requiring hospitalization in the past 6 months
- •Intubation for COPD, or other cause of respiratory failure in the past year
- •Use of immunosuppressive therapy (including oral prednisone), other than aerosolized corticosteroids, anytime within three months prior to participation
- •Evidence for an opportunistic infection/colonization of the airways, i.e., non-bacterial
- •Use of aerosolized corticosteroids with an inability to maintain inhaled corticosteroid therapy dosing without change during the study interval
- •Evidence for systemic illness including hematologic disorders (defined by an absolute neutrophil count (ANC) < 4000 /mL and platelets < 120,000/mL), renal insufficiency (serum creatinine > 2.0 mg/dL), cirrhosis, or hepatic insufficiency (total bilirubin, or alkaline phosphatase > 1.5 x normal, SGOT, or SGPT > 1.2 x normal values), or a coagulopathy (INR > 1.4), seizure disorder.
- •Evidence for systemic abnormal renal function manifested by uncontrolled hypertension (systolic blood pressure > 160mmHg or diastolic blood pressure >90mmHg), hyperkalemia (serum creatinine > 5.0 meq/dl, and/or elevated serum creatinine above the normal range for the subject's age.
- •Evidence of coronary artery disease by history, e.g., angina or history of myocardial infarction within the past 12 months, unless corrected by CABG within < 5 years, and asymptomatic since
- •Pregnant or breast feeding females or women of childbearing potential not practicing birth control during and for 6 months following treatment, or fertile and sexually active males unwilling to use contraceptive techniques during and for 6 months following treatment
- •Positive HIV, or hepatitis B or C serology, or another active infection
- •Current or past history of cancer excluding basal or squamous cell skin cancer
- •Undiagnosed pulmonary nodule requiring diagnostic evaluation
- •Weight loss > 10% usual body weight over the past 6 months or a BMI < 18
- •Known hypersensitivity or allergy to propylene glycol, CsA, or lidocaine
- •Concurrent enrollment or participation within the prior month in other clinical trials
- •Greater than 15% or 200 ml reduction in FEV1 post test dose propylene glycol administration
- •Known medical or psychological condition (severe personality disorder or mental illness) that would not permit the subject to complete the trial or sign informed consent
- •Autoimmune disorders or other disorders with suspected systemic immune involvement
- •Active smoking history or urinary cotinine >
- •Hypersensitivity to midazolam or narcotics which would not allow bronchoscopy sedation
Arms & Interventions
Cyclosporine
Experimental
Intervention: Cyclosporine (Drug)
Placebo
Placebo Comparator
Subjects will be randomly assigned to Cyclosporine or placebo, in a ratio of 2:1.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
To evaluate the safety and effectiveness of aerosol cyclosporine (CyIS) an immunomodulating therapeutic in treating COPD
Time Frame: Short term (28 day) safety profile
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Tobramycin Inhalation Solution Administered by eFlow Rapid Nebulizer: Scintigraphy StudyCystic FibrosisNCT00399945Novartis12
Withdrawn
Phase 1
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the LungMetastatic MelanomaRecurrent MelanomaUnresectable MelanomaNCT05717140Mayo Clinic20
Active, not recruiting
Phase 1
Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy AdultsWest Nile Viral InfectionNCT06745921National Institute of Allergy and Infectious Diseases (NIAID)30
Completed
Phase 3
Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)Seasonal Allergic RhinitisHay FeverNCT01024608Teva Branded Pharmaceutical Products R&D, Inc.340
Completed
Not Applicable
A Double-Blind Placebo-Controlled Group Comparative Study To Evaluate the Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCPPneumonia, Pneumocystis CariniiHIV InfectionsNCT00002053Fisons